Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,901 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan.
Rios-Romenets S, Acosta-Baena N, Lopez L, Madrigal-Zapata L, Street H, Jakimovich L, Langbaum JB, Cho W, Reiman EM, Tariot PN, Lopera F. Rios-Romenets S, et al. Among authors: cho w. Alzheimers Dement (N Y). 2018 Jul 14;4:283-287. doi: 10.1016/j.trci.2018.06.010. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30090848 Free PMC article.
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial.
Rios-Romenets S, Giraldo-Chica M, López H, Piedrahita F, Ramos C, Acosta-Baena N, Muñoz C, Ospina P, Tobón C, Cho W, Ward M, Langbaum JB, Tariot PN, Reiman EM, Lopera F. Rios-Romenets S, et al. Among authors: cho w. J Prev Alzheimers Dis. 2018;5(1):49-54. doi: 10.14283/jpad.2017.44. J Prev Alzheimers Dis. 2018. PMID: 29405233 Free PMC article. Clinical Trial.
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.
Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM; Alzheimer's Prevention Initiative. Tariot PN, et al. Among authors: cho w. Alzheimers Dement (N Y). 2018 Mar 8;4:150-160. doi: 10.1016/j.trci.2018.02.002. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955659 Free PMC article.
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
Rios-Romenets S, Lopera F, Sink KM, Hu N, Lian Q, Guthrie H, Smith J, Cho W, Mackey H, Langbaum JB, Thomas RG, Giraldo-Chica M, Tobon C, Acosta-Baena N, Muñoz C, Ospina P, Tirado V, Henao E, Bocanegra Y, Chen K, Su Y, Goradia D, Thiyyagura P, VanGilder PS, Luo J, Ghisays V, Lee W, Malek-Ahmadi MH, Protas HD, Chen Y, Quiroz YT, Reiman EM, Tariot PN; the API ADAD Colombia Trial Group. Rios-Romenets S, et al. Among authors: cho w. Alzheimers Dement. 2020 Jul;16(7):1023-1030. doi: 10.1002/alz.12109. Epub 2020 May 17. Alzheimers Dement. 2020. PMID: 32418361 Free PMC article.
Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation.
Kosik KS, Muñoz C, Lopez L, Arcila ML, García G, Madrigal L, Moreno S, Ríos Romenets S, Lopez H, Gutierrez M, Langbaum JB, Cho W, Suliman S, Tariot PN, Ho C, Reiman EM, Lopera F. Kosik KS, et al. Among authors: cho w. Neurology. 2015 Jan 13;84(2):206-8. doi: 10.1212/WNL.0000000000001130. Epub 2014 Dec 3. Neurology. 2015. PMID: 25471389 Free PMC article. No abstract available.
Normative data stratified by age and education for a Spanish neuropsychological test battery: Results from the Colombian Alzheimer's prevention initiative registry.
Torres VL, Vila-Castelar C, Bocanegra Y, Baena A, Guzmán-Vélez E, Aguirre-Acevedo DC, Tirado V, Munoz C, Henao E, Moreno S, Giraldo M, Acosta N, Rios Romenets S, Langbaum JB, Cho W, Reiman EM, Tariot PN, Rosselli M, Quiroz YT, Lopera F. Torres VL, et al. Among authors: cho w. Appl Neuropsychol Adult. 2021 Mar-Apr;28(2):230-244. doi: 10.1080/23279095.2019.1627357. Epub 2019 Jun 23. Appl Neuropsychol Adult. 2021. PMID: 31230490 Free PMC article.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. Salloway S, et al. Among authors: cho w. Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. Alzheimers Res Ther. 2018. PMID: 30231896 Free PMC article. Clinical Trial.
Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, Suhy J, Schneider L, Seely L, Tariot P, Touchon J, Weiner M, Sampaio C, Aisen P; Task Force Participants. Vellas B, et al. J Nutr Health Aging. 2012 Apr;16(4):339-45. doi: 10.1007/s12603-012-0044-x. J Nutr Health Aging. 2012. PMID: 22499454 Free article.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R. Cummings JL, et al. Among authors: cho w. Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25. Neurology. 2018. PMID: 29695589 Free PMC article. Clinical Trial.
3,901 results